Nanotechnology in cancer therapy: Targeting the inhibition of key DNA repair pathways

Current Molecular Medicine

Volumn 10, Issue 7, 2010, Pages 626-639

  Aziz, K ^a,b   Nowsheen, S ^c,d   Georgakilas, A G ^a,e  

^a EAST CAROLINA UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d The University of Alabama at Birmingham   (United States)

^e NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Base excision repair; Cancer therapy; DNA damage; DNA repair; Double strand break repair; Inhibitors; Nanotechnology

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; BSI 201; CAPTOPRIL; CARBOPLATIN; CETUXIMAB; CISPLATIN; GEMCITABINE; IRINOTECAN; LITHIUM; OLAPARIB; PEMETREXED; TEMOZOLOMIDE; TRC 102; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER GENETICS; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG SAFETY; EXCISION REPAIR; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GLIOBLASTOMA; HUMAN; INTESTINE CANCER; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; NANOTECHNOLOGY; OVARY CANCER; PHARMACODYNAMICS; SOLID TUMOR; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; DNA REPAIR ENZYMES; DRUG DESIGN; ENZYME INHIBITORS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RADIATION, IONIZING; RADIATION, NONIONIZING; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 77958001293     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652410792630599     Document Type: Article

References (195)

1. Evans DM, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res Rev Mutat Res 2004; 567: 1-61.
2. Lim CH, Dedon PC, Deen WM. Kinetic analysis of intracellular concentrations of reactive nitrogen species. Chem Res Toxicol 2008; 21: 2134-47.
3. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett 2008; 266: 6-12.
4. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 1995; 8: 583-99.
5. Klungland A, Rosewell I, Hollenbach S, et al. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc Natl Acad Sci USA 1999; 96: 13300-5.
6. Boer J, Andressoo J, de Wit J, et al. Premature aging in mice deficient in DNA repair and transcription. Science 2002; 296: 1276-9.
7. Regulus P, Duroux B, Bayle PA, et al. Oxidation of the sugar moiety of DNA by ionizing radiation or bleomycin could induce the formation of a cluster DNA lesion. Proc Natl Acad Sci USA 2007; 104: 14032-7.
8. Povirk LF, Houlgrave CW. Effect of apurinic/apyrimidinic endonucleases and polyamines on DNA treated with bleomycin and neocarzinostatin: specific formation and cleavage at closely opposed lesions in complementary strands. Biochemistry 1988; 27: 3850-7.
9. Ward JF. The complexity of DNA damage: relevance to biological consequences. Int J Radiat Biol 1994; 66: 427-32.
10. Georgakilas AG, Haveles KS, Sophianopoulou V, et al. Alpha-particle-induced changes on the stability and size of DNA. Radiat Res 2000; 153: 258-62.
11. Georgakilas AG, Sakelliou L, Sideris EG, Margaritis LH, Sophianopoulou V. Effects of gamma rays on the stability and size of DNA. Radiat Res 1998; 150: 488-91.
12. Durante M, Gialanella G, Grossi G, et al. Influence of the shielding on the induction of chromosomal aberrations in human lymphocytes exposed to high-energy iron ions. J Radiat Res 2002; 43 (Suppl.): S107-S111.
13. Cadet J, Douki T, Gasparutto D, Ravanat J. Oxidative damage to DNA: formation, measurement and biochemical features. Mutat Res 2003; 531: 5-23.
14. Sedelnikova OA, Redon CE, Dickey JS, et al. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res 2010; 704: 152-9.
15. Wilson III DM, Seidman MM. A novel link to base excision repair? Trends Biochem Sci 2010; doi:10.1016/j.tibs.2010.01.003
16. Wallace SS. Enzymatic processing of radiation-induced free radical damage in DNA. Radiat Res 1998; 150 (suppl.): S60-S79.
17. Hada M, Georgakilas AG. Formation of clustered DNA damage after high-LET irradiation: A review. J Radiat Res 2008; 49: 203-10.
18. Goodhead DT. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 1994; 65: 7-17.
19. Sutherland B, Bennett PV, Sidorkina O, Laval J. DNA damage clusters induced by ionizing radiation in isolated DNA and in human cells. Proc Natl Acad Sci USA 2000; 97: 103-108.
20. Sutherland BM, Bennett PV, Sutherland JC, Laval J. Clustered DNA damages induced by X-rays in human cells. Radiat Res 2002; 157: 611-6.
21. Sutherland BM, Bennett PV, Cintron NS, et al. Clustered DNA damages induced in human hematopoietic cells by low doses of ionzining radiation. J Radiat Res 2002; 43: S149-52.
22. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999; 286: 1897-905.
23. Dianov GL, O'Neill P, Goodhead DT. Securing genome stability by orchestrating DNA repair: removal of radiation-induced clustered lesions in DNA. BioEssays 2001; 23: 745-9.
24. Georgakilas AG. Processing of DNA damage clusters in human cells: Current status of knowledge. Mol Biosyst 2008; 4: 30-5.
25. Chaudhry MA, Weinfeld M. Reactivity of human apurinic/apyrimidinic endonuclease and Escherichia coli exonuclease III with bistranded abasic sites in DNA. J Biol Chem 1997; 272: 15650-5.
26. Harrison L, Hatahet Z, Wallace S. In vitro repair of synthetic ionizing radiation-induced multiply damaged DNA sites. J Mol Biol 1999; 290: 667-84.
27. McKenzie AA, Strauss PR. Oligonucleotides with bistranded abasic sites interfere with substrate binding and catalysis by human apurinic/apyrimidinic endonuclease. Biochemistry 2001; 40: 13254-61.
28. David-Cordonnier MH, Cunniffe SMT, Hickson ID, O'Neill P. Efficiency of incision of an AP site within clustered DNA damage by the major human AP endonuclease. Biochemistry 2002; 41: 634-42.
29. Georgakilas AG, Bennett PV, Sutherland BM. High efficiency detection of bistranded abasic clusters in -irradiated DNA by putrescine. Nucleic Acids Res 2002; 30: 2800-8.
30. Eot-Houllier G, Eon-Marchais S, Gasparutto D, Sage E. Processing of a complex multiply damaged DNA site by human cell extracts and purified repair proteins. Nucleic Acids Res 2005; 33: 260-71.
31. Georgakilas AG, Bennett PV, Wilson III DM, Sutherland BM. Processing of bistranded abasic DNA clusters in gamma-irradiated human hematopoietic cells. Nucleic Acids Res 2004; 32: 5609-20.
32. Semenenko VA, Stewart RD, Ackerman EJ. Monte Carlo simulation of base and nucleotide excision repair of clustered DNA damage sites. I. Model properties and predicted trends. Radiat Res 2005; 164: 180-93.
33. Ward JF. Some biochemical consequences of the spatial distribution of ionizing radiation produced free radicals. Radiat Res 1981; 86: 185-195.
34. Ward JF. Biochemistry of DNA lesions. Radiat Res 1985; 104: S103-11.
35. Malyarchuk S, Harrison L. DNA repair of clustered Uracils in HeLa cells. J Mol Biol 2005; 345: 731-43.
36. Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD. Genomic instability in histologically normal breast tissues: implication for carcinogenesis. Lancet Oncol 2004; 5: 753-8.
37. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-23.
38. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276-85.
39. Xu C, Maxwell BA, Brown JA, Zhang L, Suo Z. Global conformational dynamics of a Y-Family DNA polymerase during catalysis. PLoS Biol 2009; 7: e1000225.
40. Kamiya H, Yamaguchi A, Suzuki T, Harashima H. Roles of specialized DNA polymerases in mutagenesis by 8-hydroxyguanine in human cells. Mutat Res 2010; 686: 90-5.
41. Maynard S, Schurman SH, Harboe C, de Souza-Pinto NC, Bohr VA. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 2009; 30: 2-10.
42. Jung-Suk S, Bruce D. Roles of base excision repair subpathways in correcting oxidized abasic sites in DNA. FEBS J 2006; 273: 1620-9.
43. Blaisdell JO, Wallace S. Abortive base-excision repair of radiation-induced clustered DNA lesions in Escherichia coli. Proc Natl Acad Sci USA 2001; 98: 7426-30.
44. Yang N, Galick H, Wallace SS. Attempted base excision repair of ionizing radiation damage in human lymphoblastoid cells produces lethal and mutagenic double strand breaks. DNA Repair 2004; 3: 1323-34.
45. Gulston M, deLara C, Jenner T, Davis E, O'Neill P. Processing of clustered DNA damage generates additional double-strand breaks in mammalian cells post-irradiation. Nucleic Acids Res 2004; 32: 1602-09.
46. Zheng L, Zhou M, Chai Q, et al. Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks. EMBO Res 2005; 6: 83-9.
47. Weinstein GD, Goldfaden G, Frost P. Methotrexate: Mechanism of action on DNA synthesis in psoriasis. Arch Dermatol 1971; 104: 236-43.
48. Young CW, Hodas S. Hydroxyurea: Inhibitory effect on DNA metabolism. Science 1964; 146: 1172-74.
49. Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003; 103: 645-62.
50. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti cancer Agents 2002; 2: 1-17.
51. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005; 7: 1-20.
52. Dianov G, Price A, Lindahl T. Generation of single-nucleotide repair patches following excision of uracil residues from DNA. Mol Cell Biol 1992; 12: 1605-12.
53. Robertson A, Klungland A, Rognes T, Leiros I. DNA Repair in Mammalian Cells. Cell Mol Life Sci 2009; 66: 981-93.
54. Fortini P, Pascucci B, Parlanti E, et al. Different DNA polymerases are involved in the short-and long-patch base excision repair in mammalian cells. Biochemistry 1998; 37: 3575-80.
55. Bennett SE, Sung J-S, Mosbaugh DW. Fidelity of Uracilinitiated Base Excision DNA Repair in DNA Polymerase Î - Proficient and -Deficient Mouse Embryonic Fibroblast Cell Extracts. J Biol Chem 2001; 276: 42588-600.
56. Fortini P, Dogliotti E. Base damage and single-strand break repair: Mechanisms and functional significance of short- and long-patch repair subpathways. DNA Repair 2007; 6: 398-409.
57. Petermann E, Ziegler M, Oei SL. ATP-dependent selection between single nucleotide and long patch base excision repair. DNA Repair 2003; 2: 1101-14.
58. Petermann E, Keil C, Oei SL. Roles of DNA ligase III and XRCC1 in regulating the switch between short patch and long patch BER. DNA Repair 2006; 5: 544-55.
59. Comen EA RM. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology 2010; 24: 55-62.
60. Nguewa PA, Fuertes MA, Valladares B, Alonso C, Pérez JM. Poly(ADP-Ribose) Polymerases: Homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol 2005; 88: 143-72.
61. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992; 356: 356-8.
62. de Murcia G, de Murcia MJ. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994; 19: 172-6.
63. Dantzer F, Schreiber V, Niedergang C, et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 1999; 81: 69-75.
64. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999; 342: 249-68.
65. Perrin D, Gras SP, van Hille BT, Hill BT. Expression in yeast and purification of functional recombinant human poly(ADP-RIBOSE) Polymerase(PARP). Comparative pharmacological profile with that of the rat enzyme. J Enzyme Inhib Med Chem 2000; 15: 461-9.
66. Althaus FR, Höfferer L, Kleczkowska HE, et al. Histone shuttle driven by the automodification cycle of poly(ADP- ribose)polymerase. Environ Mol Mutagen 1993; 22: 278-82.
67. Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, et al. PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 2009; 47: 13-26.
68. Du L, Zhang X, Han YY, et al. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem 2003; 278: 18426-33.
69. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res DNA Repair 2000; 460: 1-15.
70. Oliver FJ, Murcia JMd, Murcia Gd. Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease. Am J Hum Genet 1999; 64: 1282-8.
71. Szabo C, Virag L, Cuzzocrea S, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA 1998; 95: 3867-72.
72. Page CL, Sanceau J, Drapier J-C, Wietzerbin J. Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation. Biochem Biophys Res Commun 1998; 243: 451-7.
73. Hauschildt S, Scheipers P, Bessler WG, Mülsch A. Induction of nitric oxide synthase in L929 cells by tumour-necrosis factor alpha is prevented by inhibitors of poly(ADP-ribose) polymerase. Biochem J 1992; 288: 255-60.
74. Kopetz S, Mita MM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2008; 26: 3577.
75. Mahany JJJ, Lewis N, Heath EI, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2008; 26: 3579.
76. Drew Y, Plummer R. PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009; 12: 153-6.
77. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010; 16: 62-5
78. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-84.
79. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
80. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-98.
81. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
82. Xia F, Powell SN. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin Radiat Oncol 2002; 12: 296-304.
83. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003; 23: 5706-15.
84. Weterings E, Chen DJ. The endless tale of non-homologous end-joining. Cell Res 2008; 18: 114-24.
85. Weterings E, Verkaik NS, Bruggenwirth HT, Hoeijmakers JHJ, van Gent DC. The role of DNA dependent protein kinase in synapsis of DNA ends. Nucleic Acids Res 2003; 31: 7238-46.
86. Ding Q, Reddy YVR, Wang W, et al. Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA double-strand break repair. Mol Cell Biol 2003; 23: 5836-48.
87. Buck D, Malivert L, de Chasseval R, et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 2006; 124: 287-99.
88. Burma S, Chen BPC, Chen DJ. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair 2006; 5: 1042-48.
89. Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol 2006; 24: 541-70.
90. van Gent DC, Ramsden DA, Gellert M. The RAG1 and RAG2 proteins establish the 12/23 rule in V(D)J recombination. Cell 1996; 85: 107-13.
91. Zha S, Boboila C, Alt FW. Mre11: roles in DNA repair beyond homologous recombination. Nat Struct Mol Biol 2009; 16: 798-800.
92. Sartori AA, Lukas C, Coates J, et al. Human CtIP promotes DNA end resection. Nature 2007; 450: 509-14.
93. Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 2009; 459: 460-3.
94. Carson CT, Schwartz RA, Stracker TH, et al. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J 2003; 22: 6610-20.
95. Jazayeri A, Falck J, Lukas C, et al. ATM-and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8: 37-45.
96. Gu B., Chen P.L. Expression of PCNA-binding domain of CtIP, a motif required for CtIP localization at DNA replication foci, causes DNA damage and activation of DNA damage checkpoint. Cell Cycle 2009; 8: 1409-20.
97. Li X, Heyer W-D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008; 18: 99-113.
98. Whitby M. In Molecular Genetics of Recombination; Andrés Aguilera and Rodney Rothstein, Ed. New York: Springer Berlin/Heidelberg 2007; Vol. 17: pp. 169-99.
99. Sugawara N, Wang X, Haber JE. In vivo roles of Rad52, Rad54, and Rad55 proteins in Rad51-mediated recombination. Mol Cell 2003; 12: 209-19.
100. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 2008; 77: 229-57.
101. Huertas P. DNA resection in eukaryotes: deciding how to fix the break. Nat Struct Mol Biol 2010; 17: 11-6.
102. Hartlerode AJ, Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J 2009; 423: 157-68.
103. Francisco DC, Peddi P, Hair JM, et al. Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and non-malignant MCF-10A cells. Free Radical Biol Med 2008; 44: 558-69.
104. Hair JM, Terzoudi GI, Hatzi VI, et al. BRCA1 role in the mitigation of radiotoxicity and chromosomal instability through repair of clustered DNA lesions. Chem Biol Interact 2010; doi:10.1016/j.cbi.2010.03.046
105. Quanz M, Berthault N, Roulin C, et al. Small-molecule drugs mimicking DNA damage: A new strategy for sensitizing tumors to radiotherapy. Clin Cancer Res 2009; 15: 1308-16.
106. Quanz M, Chassoux D, Berthault N, et al. Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response. PLoS One 2009; 4: e6298.
107. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004; 64: 6892-9.
108. Toulany M, Dittmann K, Fehrenbacher B, et al. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair 2008; 7: 1746-56.
109. Westhoff MA, Kandenwein JA, Karl S, et al. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 2009; 28: 3586-96.
110. Peddi P, Francisco DC, Cecil A, et al. Deficient processing of clustered DNA damage in human breast cancer cells MCF-7 with silenced DNA-PKcs expression. Cancer Lett 2008; 269: 174-83.
111. Georgakilas AG. A possible role of repair proteins BRCA1 and DNA-PK in the processing of oxidative DNA damage. J Biochem Tech 2008; 1: 9-11.
112. Peddi P, Loftin CW, Dickey JS, et al. DNA-PKcs deficiency leads to persistence of oxidatively-induced clustered DNA lesions in human tumor cells. Free Radic Biol Med 2010; 48: 1435-43.
113. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006; 24: 5277-82.
114. Kiehna EN, Mulhern RK, Li C, Xiong X, Merchant TE. Changes in attentional performance of children and young adults with localized primary brain tumors after conformal radiation therapy. J Clin Oncol 2006; 24: 5283-90.
115. Deweer B, Pillon B, Pochon JB, Dubois B. Is the HM story only a remote memory? Some facts about hippocampus and memory in humans. Behav Brain Res 2001; 127: 209-24.
116. Wood GE, Young LT, Reagan LP, Chen B, McEwen BS. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc Natl Acad Sci USA 2004; 101: 3973-8.
117. Surma-aho O, Niemela M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001; 56: 1285-90.
118. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39: 789-96.
119. Yang ES, Wang H, Jiang G, et al. Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PKcs dependent repair in mice. J Clin Invest 2009; 119: 1124-35.
120. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
121. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor Gefitinib (ZD1839). Clin Cancer Res 2004; 10: 6476-86.
122. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60: 15-23.
123. Georgakilas AG, Aziz K, Ziech D, Georgakila S, Panayiotidis MI. BRCA1 involvement in toxicological responses and human cancer etiology. Toxicol Lett 2009; 188: 77-83
124. Yamayoshi Y, Iida E, Tanigawara Y. Cancer pharmacogenomics: international trends. Int J Clin Oncol 2005; 10: 5-13.
125. Park DJ, Stoehlmacher J, Zhang W, et al. A Xeroderma Pigmentosum Group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8.
126. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21: 3075-9.
127. www.Cancerindex.org.
128. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair 2004; 3: 1187-96.
129. Maura F, Edoardo L, Concetta M, et al. Unrelated hematopoietic stem cell transplantation for Cernunnos-XLF deficiency. Pediatr Transplant 2009; 13: 785-9.
130. Taylor AMR, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. DNA Repair 2004; 3: 1219-25.
131. Kleijer WJ, Van Der Kraan M, Los FJ, Jaspers NGJ. Prenatal diagnosis of ataxia-telangiectasia and Nijmegen Breakage Syndrome by the assay of radioresistant DNA synthesis. Int J Radiat Biol 1994; 66: S167-74.
132. Gennery AR. Primary immunodeficiency syndromes associated with defective DNA double-strand break repair. Br Med Bull 2006; 77-78: 71-85.
133. Lins S, Kim R, Krüger L, et al. Clinical variability and expression of the NBN c.657del5 allele in Nijmegen Breakage Syndrome. Gene 2009; 447: 12-17.
134. Masi Ad Viganotti M, Polticelli F, et al. The R215W mutation in NBS1 impairs [gamma]-H2AX binding and affects DNA repair: molecular bases for the severe phenotype of 657del5/R215W Nijmegen breakage syndrome patients. Biochem Biophys Res Commun 2008; 369: 835-40.
135. Digweed M, Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair 2004; 3: 1207-17.
136. Harfst E, Cooper S, Neubauer S, Distel L, Grawunder U. Normal V(D)J recombination in cells from patients with Nijmegen breakage syndrome. Mol Immunol 2000; 37: 915-29.
137. Teng S-C, Wu K-J, Tseng S-F, Wong C-W, Kao L. Importin KPNA2, NBS1, DNA repair and tumorigenesis. J Mol Histol 2006; 37: 293-9.
138. Lynch H, Lynch J, Lynch P, Attard T. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer 2008; 7: 27-39.
139. de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer 2005; 4: 233-237.
140. Case AS, Zighelboim I, Mutch DG, et al. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair. Gynecol Oncol 2008; 108: 438-44.
141. Plotz G, Zeuzem S, Raedle J. DNA mismatch repair and Lynch syndrome. J Mol Histol 2006; 37: 271-83.
142. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76: 1-18.
143. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPPementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11: 42-65.
144. Li F, Fraumeni JJ. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71: 747-52.
145. Scotto J, Fears TR, Fraumeni JFJ. Incidence of nonmelanoma skin cancer in the United States, ed. Bethesda: NIH 1981.
146. Bischoff FZ, Yim SO, Pathak S, et al. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 1990; 50: 7979-84.
147. Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
148. Srivasta S, Sou Z, Pirollo K, Blattner W, Chang EH. Germline transmission of a mutated p53 gene in a cancer prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-9.
149. Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res 2009; 681: 299-307.
150. Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 1996; 5: 239-46.
151. Siitonen HA, Kopra O, Kaariainen H, et al. Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases. Hum Mol Genet 2003; 12: 2837-44.
152. Wirtenberger M, Frank B, Hemminki K, et al. Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis 2006; 27: 1655-60.
153. Saintigny Y, Makienko K, Swanson C, Emond MJ, Monnat RJ, Jr. Homologous recombination resolution defect in Werner syndrome. Mol Cell Biol 2002; 22: 6971-78.
154. Perry JJP, Fan L, Tainer JA. Developing master keys to brain pathology, cancer and aging from the structural biology of proteins controlling reactive oxygen species and DNA repair. Neuroscience 2007; 145: 1280-99.
155. Rudolf J, Rouillon C, Schwarz-Linek U, White MF. The helicase XPD unwinds bubble structures and is not stalled by DNA lesions removed by the nucleotide excision repair pathway. Nucleic Acids Res 2009; gkp1058.
156. Ahmed FE, Setlow RB. DNA Repair in xeroderma pigmentosum cells treated with combinations of ultraviolet radiation and N-acetoxy-2-acetyl-aminofluorene. Cancer Res 1979; 39: 471-9.
157. Sutherland BM, Oliver R, Fuselier CO, Sutherland JC. Photoreactivation of pyrimidine dimers in the DNA of normal and Xeroderma Pigmentosum cells. Biochemistry 1976; 15: 402-6.
158. Kraemer KH. Lessions learned from xeroderma pigmentosum. J Photochem Photobiol 1996; 63: 420-2.
159. Epstein JH, Fukuyama K, Reed WB, Epstein WL. Defect in DNA synthesis in skin of patients with xeroderma pigmentosum demonstrated in vivo. Science 1980; 168: 1477-8.
160. Kuhnlein U, Lee B, Penhoet EE, Linn S. Xeroderma pigmentosum fibroblasts of the D group lack an apurinic DNA endonuclease species with a low apparent Km. Nucleic Acids Res 1978; 5: 951-60.
161. Satoh M, Jones C, Wood R, Lindahl T. DNA excision-repair defect of xeroderma pigmentosum prevents removal of a class of oxygen free radical-induced base lesions. Proc Natl Acad Sci USA 1993; 90: 6335-9.
162. Wang J-H, Yun C, Kim S, et al. Reactive oxygen species modulates the intracellular level of HBx viral oncoprotein. Biochem Biophys Res Commun 2003; 310: 32-39.
163. Broberg K, Huynh E, Engstrom K, et al. Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer 2009; 9: 140.
164. German J. Bloom syndrome: a mendelian prototype of somatic mutational disease. Medicine (Baltimore) 1993; 72: 393-406.
165. Wu L, Hickson ID. The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature 2003; 426: 870-4.
166. Meetei AR, Sechi S, Wallisch M, et al. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 2003; 23: 3417-3426.
167. Yin J, Sobeck A, Xu C, et al. BLAP75, an essential component of Bloom's syndrome protein complexes that maintain genome integrity. EMBO J 2005; 24: 1465-76.
168. Ralf C, Hickson ID, Wu L. The Bloom's syndrome helicase can promote the regression of a model replication fork. J Biol Chem 2006; 281: 22839-46.
169. Dietschy T, Shevelev I, Stagljar I. The molecular role of the Rothmund-Thomson-, RAPADILINO-and Baller-Gerold-gene product, RECQL4: recent progress. Cell Mol Life Sci 2007; 64: 796-802.
170. Leadon SA, Cooper PK. Preferential repair of ionizing radiation-induced damage in the transcribed strand of an active human gene is defective in Cockayne syndrome. Proc Natl Acad Sci USA 1993; 90: 10499-503.
171. Cooper PK, Nouspikel T, Clarkson SG, Leadon SA. Defective transcription -coupled repair or oxidative base damage in Cockayne syndrome patients from XP group G. Science 1997; 275: 990-3.
172. Dianov G, Bischoff C, Sunensen M, Bohr V. Repair of 8-oxoguanine in DNA is deficient in Cockayne syndrome group B cells. Nucleic Acids Res 1999; 27: 1365-8.
173. Weidenheim KM, Dickson DW, Rapin I. Neuropathology of Cockayne syndrome: Evidence for impaired development, premature aging, and neurodegeneration. Mech Ageing Dev 2009; 130: 619-36.
174. Stevnsner T, Muftuoglu M, Aamann MD, Bohr VA. The role of Cockayne Syndrome group B (CSB) protein in base excision repair and aging. Mech Ageing Dev 2008; 129: 441-8.
175. Frosina G. The current evidence for defective repair of oxidatively damaged DNA in Cockayne syndrome. Free Radic Biol Med 2007; 43: 165-77.
176. Ropolo M, Degan P, Foresta M, et al. Complementation of the oxidatively damaged DNA repair defect in Cockayne syndrome A and B cells by Escherichia coli formamidopyrimidine DNA glycosylase. Free Radic Biol Med 2007; 42: 1807-17.
177. Francis MA, Bagga PS, Athwal RS, Rainbow AJ. Incomplete complementation of the DNA repair defect in cockayne syndrome cells by the denV gene from bacteriophage T4 suggests a deficiency in base excision repair. Mutat Res DNA Repair 1997; 385: 59-74.
178. Hanawalt PC. DNA repair: The bases for Cockayne syndrome. Nature 2000; 405: 415-415.
179. Dollfus H, Porto F, Caussade P, et al. Ocular Manifestations in the Inherited DNA Repair Disorders. Surv Ophthalmol 2003; 48: 107-22.
180. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insights. Mutat Res 2009; 668: 54-72.
181. Green AM, Kupfer GM. Fanconi anemia. Hematol Oncol Clin North Am 2009; 23: 193-214.
182. Collis SJ, Ciccia A, Deans AJ, et al. FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex. Mol Cell 2008; 32: 313-24.
183. Martinez A, Hinz JM, Gómez L, et al. Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res 2008; 656: 1-7.
184. Vilcheck SK, Ceryak S, O'Brien TJ, Patierno SR. FANCD2 monoubiquitination and activation by hexavalent chromium [Cr(VI)] exposure: Activation is not required for repair of Cr(VI)-induced DSBs. Mutat Res 2006; 610: 21-30.
185. Mirchandani KD, D'Andrea AD. The Fanconi anemia/BRCA pathway: A coordinator of cross-link repair. Exp Cell Res 2006; 312: 2647-53.
186. Macé G, Bogliolo M, Guervilly J-H, et al. 3R coordination by Fanconi anemia proteins. Biochimie 2005; 87: 647-58.
187. Wang X, D'Andrea AD. The interplay of Fanconi anemia proteins in the DNA damage response. DNA Repair 2004; 3: 1063-9.
188. Chistiakov DA, Voronova NV, Chistiakov AP. Ligase IV syndrome. Eur J Med Genet 2009; 52: 373-8.
189. O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. DNA Repair 2004; 3: 1227-35.
190. Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 2002; 11: 1399-407.
191. Wu W, Wang M, Wu W, et al. Repair of radiation induced DNA double strand breaks by backup NHEJ is enhanced in G2. DNA Repair 2008; 7: 329-38.
192. Gatti R, Boder E, Good R. Immunodeficiency, radiosensitivity, and the XCIND syndrome. Immunol Res 2007; 38: 87-101.
193. Faivre L, Merrer ML, Lyonnet S, et al. Clinical and genetic heterogeneity of Seckel syndrome. Am J Med Genet 2002; 112: 379-83.
194. clinicaltrials.gov.
195. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 83-105.